ResMed Inc. (NYSE:RMD - Free Report) - Equities researchers at Zacks Research upped their FY2025 earnings estimates for ResMed in a research report issued on Monday, April 14th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings per share of $9.38 for the year, up from their prior estimate of $9.37. The consensus estimate for ResMed's current full-year earnings is $9.47 per share. Zacks Research also issued estimates for ResMed's Q4 2025 earnings at $2.43 EPS, Q1 2026 earnings at $2.33 EPS, Q2 2026 earnings at $2.42 EPS, FY2026 earnings at $9.72 EPS, Q2 2027 earnings at $2.62 EPS and FY2027 earnings at $10.66 EPS.
RMD has been the topic of a number of other research reports. KeyCorp increased their price target on shares of ResMed from $266.00 to $280.00 and gave the company an "overweight" rating in a report on Friday, January 31st. Piper Sandler lifted their price objective on ResMed from $252.00 to $260.00 and gave the stock a "neutral" rating in a report on Friday, January 31st. Morgan Stanley began coverage on shares of ResMed in a report on Wednesday, March 19th. They set an "overweight" rating and a $280.00 price target on the stock. UBS Group upgraded shares of ResMed from a "hold" rating to a "strong-buy" rating in a research report on Friday, January 31st. Finally, Stifel Nicolaus lowered their price target on ResMed from $250.00 to $240.00 and set a "hold" rating on the stock in a report on Wednesday, March 5th. One analyst has rated the stock with a sell rating, five have given a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $251.00.
Check Out Our Latest Analysis on ResMed
ResMed Stock Up 0.7 %
ResMed stock traded up $1.40 during mid-day trading on Tuesday, reaching $212.89. The stock had a trading volume of 1,109,562 shares, compared to its average volume of 1,024,057. The company has a market capitalization of $31.27 billion, a price-to-earnings ratio of 25.13, a PEG ratio of 1.53 and a beta of 0.75. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.29. ResMed has a one year low of $176.92 and a one year high of $263.05. The company has a 50-day moving average price of $223.12 and a two-hundred day moving average price of $234.52.
ResMed (NYSE:RMD - Get Free Report) last announced its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%.
Institutional Trading of ResMed
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. MML Investors Services LLC lifted its position in shares of ResMed by 3.1% in the third quarter. MML Investors Services LLC now owns 8,697 shares of the medical equipment provider's stock worth $2,123,000 after buying an additional 260 shares in the last quarter. SkyView Investment Advisors LLC increased its stake in ResMed by 2.0% in the 3rd quarter. SkyView Investment Advisors LLC now owns 2,610 shares of the medical equipment provider's stock worth $637,000 after acquiring an additional 51 shares during the last quarter. Sanctuary Advisors LLC raised its holdings in shares of ResMed by 19.7% during the 3rd quarter. Sanctuary Advisors LLC now owns 7,265 shares of the medical equipment provider's stock worth $1,771,000 after acquiring an additional 1,197 shares in the last quarter. World Investment Advisors LLC bought a new position in shares of ResMed during the 3rd quarter valued at approximately $541,000. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of ResMed in the third quarter valued at $193,000. 54.98% of the stock is currently owned by institutional investors.
Insider Activity at ResMed
In other ResMed news, insider Kaushik Ghoshal sold 9,745 shares of the company's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $239.31, for a total value of $2,332,075.95. Following the completion of the transaction, the insider now directly owns 9,725 shares in the company, valued at $2,327,289.75. This represents a 50.05 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $242.11, for a total transaction of $484,220.00. Following the sale, the director now owns 77,218 shares in the company, valued at approximately $18,695,249.98. The trade was a 2.52 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 49,013 shares of company stock worth $11,298,816. 0.71% of the stock is owned by corporate insiders.
ResMed Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th were given a dividend of $0.53 per share. The ex-dividend date was Thursday, February 13th. This represents a $2.12 annualized dividend and a dividend yield of 1.00%. ResMed's payout ratio is 25.03%.
ResMed Company Profile
(
Get Free Report)
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.
Further Reading
Before you consider ResMed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ResMed wasn't on the list.
While ResMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
